«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2023年05期

页码:

635-639

栏目:

论著

出版日期:

2023-10-20

文章信息/Info

Title:

Clinicopathological features and therapeutic efficacy of non-small cell lung cancer with uncommon EGFR mutation

作者:

游雅婷; 毕周奎; 郭 亮; 白 莉

400037 重庆,陆军(第三)军医大学第二附属医院呼吸与危重症医学科

Author(s):

You Yating;  Bi Zhoukui;  Guo Liang;  Bai Li.

Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China

关键词:

非小细胞肺癌;  表皮生长因子受体罕见突变;  一线酪氨酸激酶抑制剂

Keywords:

Non-small cell lung cancer;  Uncommon epidermal growth factor receptor mutations;  First-line tyrosine kinase inhibitor

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2023.05.006

摘要:

目的 分析非小细胞肺癌(non-small cell lung cancer, NSCLC)表皮生长因子受体(epidermal growth factor receptor, EGFR)罕见突变的临床病理特征及一线酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)治疗疗效。方法 选择2017年8月至2023年7月我院收治的Ⅲb-Ⅳ期NSCLC罕见EGFR突变患者51例,分析临床病理特征,按治疗方法分为TKI治疗组42例、化疗组5例、姑息性治疗组4例,分析无进展生存期(progression-free survival, PFS)、总生存期(overall survival, OS)、客观缓解率(objective response rate, ORR)。结果 51例罕见突变患者中20外显子插入(20ins)12例,主要罕见突变21例,复合突变18例。主要罕见突变L861Q 11例(22%),罕见复合突变G719X+S768I 8例(16%)。化疗组ORR为25%,低于靶向治疗组ORR 38.1%。TKI治疗对主要罕见突变(mPFS=16个月,IQR 9～21; mOS=19个月,IQR 14～28)和复合突变(mPFS=15个月,IQR 8～20; mOS=20个月,IQR 15～25)疗效较好。TKI治疗对20ins疗效较差(mPFS=4个月,IQR 2～7; mOS=6个月,IQR 3～7)。化疗对主要罕见突变和复合突变(mPFS=6个月,IQR 1-12; mOS=16个月,IQR 15-19)较TKI治疗好(P<0.001)。结论 EGFR罕见突变对非小细胞肺癌一线治疗反应和生存期有重要影响。主要罕见突变和复合突变TKI治疗比化疗PFS和OS长。20 ins对TKI治疗反应差。

Abstract:

Objective To analyze the clinicopathological features of uncommon epidermal growth factor receptor(EGFR)mutations in non-small cell lung cancer(NSCLC)and the therapeutic efficacy of first-line tyrosine kinase inhibitors(TKI). Methods All of 51 patients with uncommon EGFR mutation in stage Ⅲb-Ⅳ NSCLC treated in our hospital from August 2017 to July 2023 were selected. The clinicopathological characteristics were analyzed. According to treatment methods, it was divided into TKI treatment group(42 cases), chemotherapy group(5 cases)and palliative treatment group(4 cases). Progression-free survival(PFS), overall survival(OS)and objective response rate(ORR)were analyzed. Results Among the 51 patients with uncommon mutations, 12 had 20 exon insertions(20 ins), 21 had major uncommon mutations, and 18 had complex mutations. There were 11 cases(22%)of uncommon mutation L861Q and 8 cases(16%)of uncommon complex mutation G719X+S768I. The ORR of the chemotherapy group was 20%, lower than that of the targeted therapy group, which was 38.1%. TKI treatment for major uncommon mutations(mPFS=16 months, IQR 9-21; mOS=19 months, IQR 14-28)and complex mutations(mPFS=15 months, IQR 8-20; mOS=20 months, IQR 15～25)showed better efficacy. TKI treatment was less effective for 20 ins(mPFS=4 months, IQR 2-7; mOS=6 months, IQR 3～7). Chemotherapy for major uncommon mutations and complex mutations(mPFS=6 months, IQR 1-12; mOS=16 months, IQR 15-19)was better than TKI treatment(P<0.001). Conclusion Specific types of uncommon mutations in NSCLC patients with uncommon EGFR mutations have significant implications for treatment response and survival. Patients with major uncommon mutations and uncommon compound mutations demonstrated prolonged progression-free survival and overall survival when treated with TKIs, whereas patients with 20 exon insertions showed a suboptimal response to TKI treatment.

参考文献/References:

1 褚代芳, 金发光. 肺腺癌EGFR基因19、21外显子突变与临床病理特征及预后的关系[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(6): 711-716.
2 Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA, 2014, 311(19): 1998-2006.
3 Kohsaka S, Nagano M, Ueno T, et al. A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer[J]. Sci Transl Med, 2017, 9(416): eaan6566.
4 Yang JC, Schuler M, Popat S, et al. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases[J]. J Thorac Oncol, 2020, 15(5): 803-815.
5 王 康, 胡雪婷, 罗 虎, 等. 晚期肺腺癌患者维持治疗中EGFR-TKI联合放疗的回顾性分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(1): 17-23.
6 Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7): 830-838.
7 Passaro A, Mok T, Peters S, et al. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations[J]. J Thorac Oncol, 2021, 16(5): 764-773.
8 Kulkarni AA, Fujioka N, Reinhardt L, et al. Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC[J]. Lung Cancer Manag, 2022, 11(1): LMT54.
9 Satoh H, Miyazaki K, Sato Y, et al. Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations[J]. Turk Thorac J, 2022, 23(5): 364-365.
10 Wang H, Yu Q, Shi L, et al. NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report[J]. Front Oncol, 2022, 12: 1054593.
11 Belani N, Liang K, Fradley M, et al. How to treat EGFR-mutated non-small cell lung cancer[J]. JACC CardioOncol, 2023, 5(4): 542-545.
12 Velez MA, Burns TF. Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? [J]. Transl Lung Cancer Res, 2019, 8(Suppl 4): S339-S342.
13 Wang Z, Zhou F, Xu S, et al. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis[J]. Cancer Med, 2023, doi: 10.1002/cam4.6453.
14 Hondelink LM, Ernst SM, Atmodimedjo P, et al. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy[J]. Eur J Cancer, 2023, 181: 53-61.
15 Nicos M, Wojas-Krawczyk K, Krawczyk P, et al. Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma[J]. Arch Med Sci, 2020, 16(6): 1496-1500.
16 Jang YJ, Kim SY, Jung HK, et al. Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors[J]. Transl Cancer Res, 2021, 10(12): 5204-5211.
17 Passaro A, Janne PA, Mok T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer[J]. Nat Cancer, 2021, 2(4): 377-391.
18 Brueckl WM, Reck M, Schafer H, et al. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study[J]. J Geriatr Oncol,2023, 14(1): 101394.
19 Araki T, Kanda S, Komatsu M, et al. Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase Ⅱ trial protocol(REAL study)[J]. Transl Lung Cancer Res, 2023, 12(6): 1320-1327.
20 Hsu PC, Lee SH, Chiu LC, et al. Afatinib in untreated stage ⅢB/Ⅳ lung adenocarcinoma with major uncommon epidermal growth factor receptor(EGFR)mutations(G719X/L861Q/S768I): A multicenter observational study in Taiwan[J]. Target Oncol, 2023, 18(2): 195-207.
21 Wu YL, Sequist LV, Hu CP, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6[J]. Br J Cancer, 2017, 116(2): 175-185.
22 Song Z, Ren G, Wang X, et al. Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V mutation-mediated resistance towards osimertinib: a case report and literature review[J]. Ann Palliat Med, 2022, 11(3): 1126-1134.
23 Chen CH, Chang JW, Chang CF, et al. Real-world Afatinib outcomes in advanced non-small cell lung cancer Harboring EGFR mutations[J]. Anticancer Res, 2022, 42(4): 2145-2157.
24 Wang LS, Chen SQ, Zhong X, et al. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M[J]. Anticancer Drugs 2022, doi: 10.1097/CAD.0000000000001489.
25 Cui Y, Wang R, Wei Y, et al. Structure optimization and discovery of novel compound for the treatment of insertion mutations within exon 20 of EGFR and HER2[J]. Bioorg Med Chem, 2023, 81: 117202.
26 Yang M, Xu X, Cai J, et al. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors[J]. Int J Cancer, 2016, 139(1): 171-176.
27 Watanabe N, Horio Y, Fujiwara Y. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review[J]. Ann Transl Med, 2022, 10(23): 1283.
28 Skrickova J, Pesek M, Opalka P, et al. Prognostic value of EGFR Exon-20 insertions in czech patients with advanced non-small cell lung cancer[J]. Anticancer Res, 2021, 41(11): 5625-5634.
29 Chen Y, Jiang B, He Y, et al. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib[J]. BMC Med Genomics, 2022, 15(1): 141.
30 Low JL, Lim SM, Lee JB, et al. Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations[J]. Ther Adv Med Oncol, 2023, 15: 17588359221146131.
31 Sentana-Lledo D, Academia E, Viray H, et al. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates[J]. Transl Lung Cancer Res, 2023, 12(7): 1590-1610.
32 Yan H, Zhu GY, Wong M, et al. Computational platform for modelling, analysis, and prediction of anti-EGFR drug resistance for lung cancer[J]. Hong Kong Med J, 2019, 25 Suppl 9(6): 40-42.

备注/Memo

备注/Memo:

通信作者: 郭 亮, Email: 283091780@qq.com
白 莉, Email: blpost@126.com

常用功能

更新日期/Last Update: 2023-10-20